Nefecon and Ambrisentan in IgA Nephropathy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Nefecon and Ambrisentan in IgA Nephropathy — Stella

Home/IgA Nephropathy/

View on ClinicalTrials.gov

Recruiting

Back to IgA Nephropathy trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

China

The First Hospital of Jilin University, Changchun, Jilin

Key details

Phase

Post-approval study

Sponsor

The First Hospital of Jilin University

Enrollment target

~129 participants

Started

September 2025

Primary completion

December 2026

Age range

18 Years – 70 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.